Xerava
Payments companies reported to CMS as associated with Xerava. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Xerava, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Xerava
These are the largest totals companies reported as associated with Xerava. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Michael Gelfand | Memphis, TN | Infectious Disease | $41,228.70 |
| Juan Diaz | Altamonte Springs, FL | Infectious Disease | $24,670.81 |
| Arthur Jeng | Sylmar, CA | Infectious Disease | $10,553.13 |
| Samir Awad | Houston, TX | Surgical Critical Care | $10,137.77 |
| Miguel Sierra-Hoffman | Victoria, TX | Infectious Disease | $9,383.24 |
| Bruce Friedman | Augusta, GA | Critical Care Medicine (Internal Medicine) | $8,380.57 |
| Martin Gnoni | Louisville, KY | Infectious Disease | $8,307.70 |
| Charles Rose | Lexington, KY | Infectious Disease | $7,911.77 |
| Christopher Cooper | Altamonte Springs, FL | Infectious Disease | $7,881.32 |
| Louis Guzzi | Orlando, FL | Critical Care Medicine (Anesthesiology) | $7,037.50 |
Prescribed Xerava?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.